Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.45 |
| ▸ | MME | P08473 | 7/20 | 0.37 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 2/20 | 0.32 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386274 | 0.83 | MME (0.44) | TGFBR1MMESLC15A2ECE1 | |
| SCHEMBL3396644 | 0.81 | MME (0.45) | TGFBR1MMEECE1 | |
| SCHEMBL3396651 | 0.81 | MME (0.45) | TGFBR1MMEECE1 | |
| SCHEMBL4082850 | 0.81 | TGFBR1 (0.39) | TGFBR1MMENOD1 | |
| SCHEMBL12292801 | 0.81 | NOD1 (0.46) | TGFBR1MMENOD1ECE1 | |
| SCHEMBL4086458 | 0.79 | TGFBR1 (0.50) | TGFBR1MMESLC15A2CA2CA1 | |
| SCHEMBL29456599 | 0.79 | TGFBR1 (0.50) | TGFBR1MMESLC15A2CA2CA1 | |
| SCHEMBL783082 | 0.78 | TGFBR1 (0.57) | TGFBR1MMECA2CA1 | |
| SCHEMBL29556650 | 0.78 | TGFBR1 (0.57) | TGFBR1MMECA2CA1 | |
| SCHEMBL783083 | 0.78 | TGFBR1 (0.57) | TGFBR1MMECA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | TGFBR1 2913/4885MME 965/4885SLC15A2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.